Professional Profile
Dr. Nate Collins is a Senior Consultant in ToxStrategies’ Biopharmaceuticals/Pharmaceuticals Practice. He has 25 years’ experience in the industry, working at four major pharmaceutical companies. He is a trained veterinary clinical pathologist and has held leadership roles in diverse areas, including pathology, immunotoxicology, investigative/mechanistic toxicology, and genetic toxicology. Most recently, Dr. Collins served as vice president for nonclinical safety, where he was responsible for the nonclinical strategy for his company’s development portfolio. In this capacity, he oversaw a team of 35 toxicologists, advising and approving nonclinical testing strategy and data interpretation, and managing regulatory interactions with international health authorities.
Dr. Collins holds a Doctor of Veterinary Medicine degree from Colorado State University, and a Doctor of Philosophy degree from The Ohio State University. He is also a Diplomate of the American College of Veterinary Pathologists (Clinical Pathology).
Dr. Collins has experience across multiple therapy areas (including oncology, immunology, neurology, anti-viral, fibrosis, and cardiovascular) and modalities (including small molecules, mAbs, fusion proteins, TCEs, cell therapy, gene therapy, ASOs, and macromolecular peptides). He has made substantial contributions to developing and/or securing approvals for CLARINEX (desloratidine), NOXAFIL (posaconazole), ZETIA (ezetimibe), VYTORIN (ezeteimbe + simvastatin), VICTRELIS (boceprivir), REBETOL (ribavirin), PEGINTRON (pegylated interferon), KEYTRUDA (pembrolizumab), ABRAXANE (paclitaxel), INREBIC (fedratinib), POMALYST (pomalidomide), ZEPOSIA (ozanimod), IDHIFA (enasidenib), REBLOZYL (luspatercept-aamt), OPDUALAG (nivolumab and relatlimab-rmbw), CAMZYOS (mavacamten), SOTYKTU (deucravacitinib), ABECMA (idecabtagene vicleucel), and BREYANZI (lisocabtagene maraleucel), as well as numerous other development candidates, from preclinical through Phase 3 clinical development and post-marketing commitments. He has also served on committees and/or leadership roles for several professional organizations and consortia, including ACVP, ILSI-HESI, PhRMA, and PSTC.